Findings

What do systematic reviews say?

1 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + nateglinide

4 findings from 1 review

Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 233 participants
Very low
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 874 participants
Low
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 446 participants
Low

Show 1 more finding

Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
RR 1.68 [0.54, 5.21]
3 studies · 874 participants
Low